ACAD Q2 2022 Earnings — ACADIA Pharmaceuticals Inc. Revenue & Financial Results | Market Cap Arena

ACADACADIA Pharmaceuticals Inc.

$4B

Q2 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$135M+16.8% YoY

Gross Profit

$132M98.0% margin

Operating Income

-$34M-25.0% margin

Net Income

-$34M-25.3% margin

EPS (Diluted)

$-0.21

QoQ Revenue Growth

+16.5%

Cash Flow

Operating Cash Flow

-$13M

Free Cash Flow

-$13M

Stock-Based Comp.

$21M

Balance Sheet

Total Assets

$613M

Total Liabilities

$178M

Stockholders' Equity

$435M

Cash & Equivalents

$140M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$135M	$115M	+16.8%
Gross Profit	$132M	$110M	+19.9%
Operating Income	-$34M	-$44M	+23.0%
Net Income	-$34M	-$44M	+22.5%